Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

• Status: Unknown status
• Trial end date: 2021-01-11
• Target enrollment: 0
• Participant gender: All

Summary

Due to the great toxicity of chemotherapeutic drugs to both the healthy and cancerous area, the efficient targeting could be of great benefit for a patient with advanced or metastatic tumors. Colorectal cells carry somatostatin receptors which make them a promising target for antitumor therapy since this would reduce side effects and increase drug delivery efficacy to the target site.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ahmed A. H. Abdellatif
• Treatments: Cetuximab; Somatostatin

Criteria

Inclusion Criteria:

• Clinical diagnosis of colon cancer

• Follow up and collect data for a local and systemic activity of cetuximab

• The systemic oral capsule of cetuximab be also given to enhance the activity as an anti-cancer activities

Exclusion Criteria:

• Peptic ulcer

• Stomach disease

• Colon cancer